aducanumab - Alzheimer’s

Has anybody Here on the inside at Eisai been involved in discussions on what part of promotions Eisai will play if aducanumab gets approved by the FDA? Will it be Biogen or Eisai promoting? What divisions? Will the new sales force for primary care at Eisai be selling it in that space?

 

I’m curious about this too... what is Eisai’s role in this product, and if approved would Eisai be involved in the sales at all? They don’t even mention us. But it’s in our “pipeline”.

https://www.fiercepharma.com/pharma/a-192m-moat-buffett-s-berkshire-builds-stake-biogen-ahead-key-alzheimer-s-drug-filing

 

I’m at Biogen and curious about this as well. Nobody knows anything but it’s looking like Easai will co-market but not co-promote.

 

I’m at Biogen and curious about this as well. Nobody knows anything but it’s looking like Easai will co-market but not co-promote.

 

Never. Getting. Approved.

 

The data is pretty sketchy. Only looking at patients who completed trial on high dose for a certain duration. If you look at the ITT population there is no clear benefit but clear harm. If approved one could only conclude that the FDA gave in to political pressure. Biogen is very desperate after losing patent protection to their best seller Tecfidera.

 

This drug is a dog at best

 

What are hearing about this launch? Biogen is starting there 2nd wave of hiring.

 

Biogen paid for priority review and the FDA can technically wait until March 2021 before a decision is made. They have hired majority of sales force but some positions still posted.

 

Everyone has an opinion. Time will tell. Last Biogen launch in MS did not go well. Why believe this one will be any better?

 

The FDA will issue a CRL in the coming months. There will be some back and forth with the agency and then the program will be quietly terminated.

 

They are hiring virtual reps for this position, what is the pay range??

 

WTH this is another repetitive Biogen thread on the Eisai site. Dumb

 

RBC's Brian Abrahams holds a mock adcomm on Biogen's iffy aducanumab data — and most of these experts don't see a path to an approval

 

Poof...

 

Alex did the dude.

 

By the way, Biogen has halted everything. They have even dismantled a few things. Looks like the data may not be enough to pull this indication through. Even if it were to happen, it will not be enough to justify using it.

 

It’s done. Move on.

 

Danali just put an end to our approval. Biogen just got the news they didn't want.

 

Yes, a mouse study put an end to approval for a PhIII asset.

Moron.